Point72 Asia (Singapore)’s Sage Therapeutics SAGE Stock Holding History

Point72 Asia (Singapore)’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-44,310	Closed	-$404K	–	1197
2025 Q2	$404K	Buy	44,310 +21,477	+94%	+$158K	0.07%	230
2025 Q1	$182K	Buy	22,833 +2,192	+11%	+$16K	0.05%	293
2024 Q4	$112K	Buy	+20,641	New	+$126K	0.03%	350
2024 Q3	–	Sell	-21,806	Closed	-$237K	–	1270
2024 Q2	$237K	Buy	21,806 +21,411	+5,421%	+$274K	0.05%	257
2024 Q1	$7.4K	Buy	+395	New	+$9.11K	﹤0.01%	1013

Other funds holding SAGE

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Point72 Asia (Singapore)'s SAGE Position: Q3 2025 in Review

Point72 Asia (Singapore) sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 44,310 shares — an estimated $404K sold.

Point72 Asia (Singapore) first reported a position in SAGE in Q1 2024 and held it in 5 quarters. The position peaked at $404K in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

Point72 Asia (Singapore) reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
Point72 Asia (Singapore) sold 44,310 Sage Therapeutics shares in Q3 2025, an estimated $404K.
Point72 Asia (Singapore) first reported a position in Sage Therapeutics in Q1 2024 and held it in 5 quarters.
Point72 Asia (Singapore)'s Sage Therapeutics position peaked at $404K in Q2 2025.
5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.